GenSpera G-202 data in journal

GenSpera G-202 data published

2012-06-30

(Press-News.org) GenSpera, Inc. (OTCBB:GNSZ) announced that a study titled, "Engineering the Plant Product Thapsigargin into a PSMA-Activated Tumor Endothelial Cell Prodrug for Cancer Therapy," was published in the journal, Science Translational Medicine, on June 27, 2012 (http://stm.sciencemag.org/content/4/140/140ra86). The manuscript documents the extensive pre-clinical data and rationale for the development of G-202 as a potential treatment for a variety of solid tumors in human patients.

The paper also validated the enzyme, PSMA, as an appropriate molecular target for G-202. PSMA is expressed by both prostate cancer cells and endothelial (vascular) cells in a variety of cancers, but not by most normal tissues. Finally, the paper showed G-202 toxicity to be low in animal models. Based on these results, the researchers concluded that the G-202 cytotoxin and prodrug delivery platform produced sufficient therapeutic results to support advancing G-202 to human clinical trials.

"This publication marks the culmination of 40 years of collaborative, interdisciplinary research," said Søren Brøgger Christensen, PhD, study author, Professor at the University of Copenhagen and a member of GenSpera's Scientific Advisory Board. "We began studying the medicinal properties of the plant, Thapsia garganica, in the 1970's. Our group was the first to isolate the active ingredient, thapsigargin, elucidate its chemical structure and demonstrate that it kills tumor cells by blocking a specific intracellular calcium pump. Thapsigargin kills cells independently of their rate of cell division, which we believe can make it more effective than standard chemotherapeutic agents in treating a wide variety of human tumors."

"This paper represents a rare 'brain-to-bench-to-bedside' translational story," said John Isaacs, PhD, study author, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University and a member of GenSpera's Scientific Advisory Board. "We engineered a 'molecular grenade' to deliver the superior anti-cancer activity of thapsigargin directly to the tumor, thereby unleashing its therapeutic potential at the cancer site. We are encouraged by our remarkable results in multiple human cancer models in mice and look forward to the outcome of the ongoing human clinical study."

### About GenSpera

GenSpera, Inc. is a development stage oncology company focused on therapeutics that have the potential to deliver a potent, unique and patented drug directly to tumors. GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that appears to release the drug only within the tumor. Unlike standard cancer drugs, thapsigargin kills cells independently of their division rate, thus making it effective at killing all fast- and slow-growing cancers and cancer stem cells.

GenSpera has completed a Phase Ia dose-escalation safety and tolerability study with its lead drug, G-202, at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, the University of Wisconsin Carbone Cancer Center, and the Cancer Therapy and Research Center at the University of Texas Health Science Center in San Antonio. The study has continued into a Phase Ib dose refinement study in predominantly prostate cancer patients at the same clinical sites. GenSpera expects to initiate multiple Phase II trials for G-202 in several different types of cancer.

GenSpera's pipeline of drugs also includes G-114, G-115 and G-301, which all directly target prostate cancer.

For more information, please visit the Company's website: www.genspera.com. Cautionary Statement Regarding Forward Looking Information This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports.

ELSE PRESS RELEASES FROM THIS DATE:

University of Pittsburgh study reveals moderate doses of alcohol increase social bonding in groups

2012-06-30

PITTSBURGH-- A new study led by University of Pittsburgh researchers reveals that moderate amounts of alcohol--consumed in a social setting--can enhance positive emotions and social bonding and relieve negative emotions among those drinking. While it is usually taken for granted that people drink to reduce stress and enhance positive feelings, many studies have shown that alcohol consumption has an opposite effect. In a new paper titled "Alcohol and Group Formation: A Multimodal Investigation of the Effects of Alcohol on Emotion and Social Bonding," research shows that ...

Study finds new gene mutations that lead to enlarged brain size, cancer, autism, epilepsy

2012-06-30

SEATTLE – June 28, 2012 – A research team led by Seattle Children's Research Institute has discovered new gene mutations associated with markedly enlarged brain size, or megalencephaly. Mutations in three genes, AKT3, PIK3R2 and PIK3CA, were also found to be associated with a constellation of disorders including cancer, hydrocephalus, epilepsy, autism, vascular anomalies and skin growth disorders. The study, "De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes," was published online June 24 in Nature ...

Scientists urge new approaches to plant research

2012-06-30

EAST LANSING, Mich. -- You'd be amazed at how much you can learn from a plant. In a paper published this week in the journal Science, a Michigan State University professor and a colleague discuss why if humans are to survive as a species, we must turn more to plants for any number of valuable lessons. "Metabolism of plants provides humans with fiber, fuel, food and therapeutics," said Robert Last, an MSU professor of biochemistry and molecular biology. "As the human population grows and nonrenewable energy sources diminish, we need to rely increasingly on plants and ...

New fuel cell keeps going after the hydrogen runs out

2012-06-30

Cambridge, Mass. -– June 29, 2012 -- Imagine a kerosene lamp that continued to shine after the fuel was spent, or an electric stove that could remain hot during a power outage. Materials scientists at Harvard have demonstrated an equivalent feat in clean energy generation with a solid-oxide fuel cell (SOFC) that converts hydrogen into electricity but can also store electrochemical energy like a battery. This fuel cell can continue to produce power for a short time after its fuel has run out. "This thin-film SOFC takes advantage of recent advances in low-temperature ...

Easter Island drug raises cognition throughout life span

2012-06-30

SAN ANTONIO, Texas, U.S.A. (June 29, 2012) -- Cognitive skills such as learning and memory diminish with age in everyone, and the drop-off is steepest in Alzheimer's disease. Texas scientists seeking a way to prevent this decline reported exciting results this week with a drug that has Polynesian roots. The researchers, appointed in the School of Medicine at The University of Texas Health Science Center San Antonio, added rapamycin to the diet of healthy mice throughout the rodents' life span. Rapamycin, a bacterial product first isolated from soil on Easter Island, enhanced ...

Making the shortest light bursts leads to better understanding of nature

2012-06-30

An attosecond is a ridiculously brief sliver of time – a scant billionth of a billionth of a second. This may seem too short to have any practical applications, but at the atomic level, where electrons zip and jump about, these vanishingly short timescales are crucial to a deeper understanding of science. In a paper accepted for publication in the American Institute of Physics' journal Review of Scientific Instruments, a team of researchers describes an advanced experimental system that can generate attosecond bursts of extreme ultraviolet light. Such pulses are the ...

New study finds low rates of biopsy contribute to celiac disease underdiagnosis in US

2012-06-30

New York, NY (June 29, 2012) -- Under-performance of small bowel biopsy during endoscopy may be a major reason that celiac disease remains underdiagnosed in the United States, according to a new study published online recently in Gastrointestinal Endoscopy. Investigators at the Celiac Disease Center at Columbia University Medical Center (CUMC) found that the rate of small bowel biopsy is low in this country. "The vast majority of people with celiac disease in the United States remain undiagnosed," said lead author Benjamin Lebwohl, MD, MS, assistant professor of clinical ...

AGU journal highlights -- 29 June 2012

2012-06-30

The following highlights summarize research papers that have been recently published in Water Resources Research (WRR), Space Weather, Journal of Geophysical Research-Earth Surface (JGR-F), Journal of Geophysical Research-Atmospheres (JGR-D), Journal of Geophysical Research-Oceans (JGR-C), and Geophysical Research Letters (GRL). In this release: 1. Section of Atlantic circulation driven by transient southern Africa current 2. Prediction system to protect astronauts from solar storms 3. Streamflow changes following the 2010 Chile earthquake 4. Reanalyses find rising ...

Sandy beaches, hydrocarbon reservoirs, tectonic tilting: It's all about geology

2012-06-30

Boulder, Colo., USA – Topics in this new batch of Geology papers posted online 29 June include ecospace utilization; Little Bahama Bank; climatic asynchrony; oceanic crust; sand budgets; the Alpine fault's seismic hazard to New Zealand; volcano behavior; gravity oscillations; chemical weathering in the Critical Zone; giant wave ripples; the location of high peaks as a function of drainage network; and soils as ledgers recording transactions of energy and material between Earth's plants, rocks, water, and atmosphere. Highlights are provided below. Geology articles published ...

NASA explains why clocks will get an extra second on June 30

2012-06-30

If the day seems a little longer than usual on Saturday, June 30, 2012, that's because it will be. An extra second, or "leap" second, will be added at midnight to account for the fact that it is taking Earth longer and longer to complete one full turn--a day--or, technically, a solar day. "The solar day is gradually getting longer because Earth's rotation is slowing down ever so slightly," says Daniel MacMillan of NASA's Goddard Space Flight Center in Greenbelt, Md. Scientists know exactly how long it takes Earth to rotate because they have been making that measurement ...

GenSpera G-202 data in journal

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: